These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17326278)

  • 61. Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole.
    Dixon KS; Hassoun A
    J Am Pharm Assoc (2003); 2010; 50(6):742-4. PubMed ID: 21071321
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.
    Feist A; Lee R; Osborne S; Lane J; Yung G
    J Heart Lung Transplant; 2012 Nov; 31(11):1177-81. PubMed ID: 22841559
    [TBL] [Abstract][Full Text] [Related]  

  • 63. What is the "therapeutic range" for voriconazole?
    Lewis RE
    Clin Infect Dis; 2008 Jan; 46(2):212-4. PubMed ID: 18171252
    [No Abstract]   [Full Text] [Related]  

  • 64. Voriconazole-associated myositis.
    Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
    J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pseudoporphyria as a result of voriconazole use: a case report.
    Dolan CK; Hall MA; Blazes DL; Norwood CW
    Int J Dermatol; 2004 Oct; 43(10):768-71. PubMed ID: 15485539
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lupus-like lesions in a 28-month-old boy with chronic granulomatous disease on long-term voriconazole prophylaxis.
    Geller L; Raciti PM; Mercer SE; Phelps RG
    J Cutan Pathol; 2011 Aug; 38(8):677-8. PubMed ID: 21518384
    [No Abstract]   [Full Text] [Related]  

  • 67. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
    Brunel AS; Fraisse T; Lechiche C; Pinzani V; Mauboussin JM; Sotto A
    AIDS; 2008 Apr; 22(7):905-6. PubMed ID: 18427212
    [No Abstract]   [Full Text] [Related]  

  • 68. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients.
    Epaulard O; Saint-Raymond C; Villier C; Charles J; Roch N; Beani JC; Leccia MT
    Clin Microbiol Infect; 2010 Sep; 16(9):1362-4. PubMed ID: 19930272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/ photoaging reaction.
    Frisch S; Askari SK; Beaty SR; Burkemper CN
    J Drugs Dermatol; 2010 May; 9(5):562-4. PubMed ID: 20480802
    [TBL] [Abstract][Full Text] [Related]  

  • 70. VFEND® (voriconazole)-associated hypoglycaemia without identified drug interaction.
    Lyoen M; Rostain F; Grimault A; Minello A; Sgro C
    Fundam Clin Pharmacol; 2013 Oct; 27(5):570-1. PubMed ID: 22834415
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.
    Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ
    Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561
    [No Abstract]   [Full Text] [Related]  

  • 73. Molecular docking cannot accurately predict drug off-target effects: implications for the role of voriconazole in the exacerbation of myasthenia gravis.
    Deftereos SN
    Muscle Nerve; 2014 Jan; 49(1):147-8. PubMed ID: 24127354
    [No Abstract]   [Full Text] [Related]  

  • 74. Voriconazole-associated salt-losing nephropathy.
    Teranishi J; Nagatoya K; Kakita T; Yamauchi Y; Matsuda H; Mori T; Inoue T
    Clin Exp Nephrol; 2010 Aug; 14(4):377-80. PubMed ID: 20567873
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hallucinations during voriconazole therapy.
    Zonios DI; Gea-Banacloche J; Childs R; Bennett JE
    Clin Infect Dis; 2008 Jul; 47(1):e7-e10. PubMed ID: 18491963
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Author reply: To PMID 23666793.
    Azzam R; Katirji B
    Muscle Nerve; 2014 Jan; 49(1):148. PubMed ID: 24123082
    [No Abstract]   [Full Text] [Related]  

  • 77. Hepatotoxicity of antifungal agents.
    Song JC; Deresinski S
    Curr Opin Investig Drugs; 2005 Feb; 6(2):170-7. PubMed ID: 15751740
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Quantitative evaluation method of the informational value of initial symptoms based on Bayesian theory].
    Ohshima S; Ieda M; Yamamoto M; Kobayashi D
    Yakugaku Zasshi; 2012; 132(6):763-8. PubMed ID: 22687735
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
    Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
    Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fluconazole and phenytoin: a predictable interaction.
    Mitchell AS; Holland JT
    BMJ; 1989 May; 298(6683):1315. PubMed ID: 2544241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.